No. | Genotype, % | G Allele, % | Allelic Association | ||||
---|---|---|---|---|---|---|---|
GG | GT | TT | p | OR (95% CI) | |||
French Caucasian | |||||||
Controls | 971 | 8.5 | 38.7 | 52.8 | 27.8 | ||
Patients with SSc | 1001 | 9.2 | 41.7 | 49.1 | 30.0 | 0.13 | 1.1 (0.97–1.3) |
Limited SSc | 630 | 8.4 | 42.7 | 48.9 | 29.8 | 0.23 | 1.1 (0.9–1.3) |
Diffuse SSc | 312 | 10.9 | 40.7 | 48.4 | 31.3 | 0.10 | 1.18 (0.97–1.4) |
Autoantibodies | |||||||
Anti-centromere | 363 | 10.5 | 40.8 | 48.7 | 30.9 | 0.12 | 1.16 (0.96–1.4) |
Anti-topoisomerase I | 248 | 8.5 | 47.2 | 44.3 | 32.1 | 0.06 | 1.23 (0.99–1.5) |
US Caucasian | |||||||
Controls | 574 | 8.7 | 37.5 | 53.8 | 27.4 | ||
Patients with SSc | 1029 | 8.0 | 43.9 | 48.1 | 29.9 | 0.14 | 1.13 (0.96–1.3) |
Limited SSc | 591 | 8.5 | 43.7 | 47.9 | 30.3 | 0.13 | 1.15 (0.96–1.4) |
Diffuse SSc | 384 | 7.0 | 45.1 | 47.9 | 29.6 | 0.31 | 1.11 (0.9–1.4) |
Autoantibodies | |||||||
Anti-centromere | 290 | 9.7 | 42.4 | 47.9 | 30.9 | 0.14 | 1.18 (0.9–1.5) |
Anti-topoisomerase I | 170 | 5.3 | 50.6 | 44.1 | 30.6 | 0.26 | 1.17 (0.9–1.5) |